WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 28-May-2015 (Data received as of 22-May-2015)
Next overall update July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 12'9101 Infant (under 12 months) mortality rate: 92
GDP / capita (US$): 20'9771 Child (under 5 years) mortality rate: 102

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 91  90  89  88  87  78  62  70 
Births
Surviving infants
Pop. less than 5 years
Pop. less than 15 years 22  22  23  23  23  23  18  24 
Female 15-49 years 26  26  26  25  25  23  17  19 

Number of reported case

(Click for retrospective incidence data for Antigua and Barbuda)
Diphtheria
Japanese encephalitis
Measles 2'291 
Mumps
Pertussis
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Antigua and Barbuda)
Vaccine year result method % card seen                                                
BCG          99 
DTP1          98  90  75  90 
DTP3          99  98  99  98  95  99  54 
HepB_BD         
HepB3          98  98  99  98 
Hib3          99  98  99  98 
JapEnc         
MCV          99*  98  99*  98  95  89 
MCV2          87  90  89 
PCV1         
PCV3         
Pol3          98  97  99  99  96  99  36 
Rota1         
Rota_last         
Rubella1          99*  99*  99*  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Antigua and Barbuda)
DTP1 99  99  99  99  98  99  77 
DTP3 99  98  99  98  95  99  54 
HepB3 98  98  99  98 
HepB_BD
Hib3 99  98  98  98 
MCV 98  98  99  98  95  89 
MCV2 87  90  89  92 
PCV3
Pol3 98  97  99  99  96  99  36 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
88 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 4-5, 15 years; Yes
DTaPHibHep 2, 4, 6 months;
DTwP 18 months; Yes
HepB 1st contact; +6 weeks; +6 months;
Influenza 30-37 months; Yes and adults
MMR 12 months; 4-5, 15 years; Yes
OPV 2, 4, 6, 18 months; 4-5 years; Yes
Td 1st contact; + 6 weeks; +6 months; Yes every 10 years

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR     No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number       27 
Nº districts with DTP3 coverage >=80% number   14 
% of districts with DTP3 coverage >=80% From 0 to 100%     100  100  100   
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100%     100  100  100     

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND     Yes  Yes  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR     Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%     93  EC$90,470.62    100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR     No  No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.